GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » EV-to-FCF

Biocure Technology (XCNQ:CURE) EV-to-FCF : 6.82 (As of Apr. 16, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biocure Technology's Enterprise Value is C$0.49 Mil. Biocure Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.07 Mil. Therefore, Biocure Technology's EV-to-FCF for today is 6.82.

The historical rank and industry rank for Biocure Technology's EV-to-FCF or its related term are showing as below:

XCNQ:CURE' s EV-to-FCF Range Over the Past 10 Years
Min: -254.22   Med: -5.08   Max: 6.82
Current: 6.82

During the past 13 years, the highest EV-to-FCF of Biocure Technology was 6.82. The lowest was -254.22. And the median was -5.08.

XCNQ:CURE's EV-to-FCF is ranked worse than
57.65% of 451 companies
in the Biotechnology industry
Industry Median: 2.21 vs XCNQ:CURE: 6.82

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-16), Biocure Technology's stock price is C$0.045. Biocure Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.365. Therefore, Biocure Technology's PE Ratio (TTM) for today is At Loss.


Biocure Technology EV-to-FCF Historical Data

The historical data trend for Biocure Technology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology EV-to-FCF Chart

Biocure Technology Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.50 -23.69 -15.80 -0.96 -6.67

Biocure Technology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.94 -6.67 50.00 20.99 13.35

Competitive Comparison of Biocure Technology's EV-to-FCF

For the Biotechnology subindustry, Biocure Technology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocure Technology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocure Technology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Biocure Technology's EV-to-FCF falls into.


;
;

Biocure Technology EV-to-FCF Calculation

Biocure Technology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.491/0.072
=6.82

Biocure Technology's current Enterprise Value is C$0.49 Mil.
Biocure Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocure Technology  (XCNQ:CURE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Biocure Technology's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.045/-0.365
=At Loss

Biocure Technology's share price for today is C$0.045.
Biocure Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.365.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Biocure Technology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Biocure Technology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocure Technology Business Description

Traded in Other Exchanges
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9
Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It Developing Biosimilars and CAR-T Cell pharmaceuticals. Its products are CAR-T Cell Therapy, Interferon Beta, Ranibizumab, and PEG-Filgrastim.
Executives
Konstantin Lichtenwald Director, Senior Officer

Biocure Technology Headlines